Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL-2, Vinblastine and GM-CSF in Metastatic Renal Cell Carcinoma
NCT00003181Phase 2
Key facts
- Status
- Unknown
- Start
- May 1997
- Countries
- 1
- Sponsor
- Hope Cancer Institute, Inc.
- Modality
- Recombinant Proteins and Enzymes
- Drugs
- sargramostim
- Conditions
- renal cell carcinoma (RCC)
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in renal cell carcinoma (RCC), sponsored by Hope Cancer Institute, Inc. Primary endpoint: Response Rate. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Combination Therapy
Sargramostim + Aldesleukin + Vinblastine
03
Who it enrols
Adult patients with histologically proven inoperable, metastatic, or recurrent renal cell carcinoma, measurable disease, and adequate organ function. Excludes patients with brain metastases, significant cardiovascular or pulmonary disease, or active other malignancies.
04
Endpoints
Primary
Response Rate
Secondary
Toxicities
Beyond the preview
Go deeper on NCT00003181.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003181.